<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067262</url>
  </required_header>
  <id_info>
    <org_study_id>M01-342</org_study_id>
    <nct_id>NCT00067262</nct_id>
  </id_info>
  <brief_title>An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Depakote ER for the Treatment of Bipolar Disorder in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of Depakote ER
      (Divalproex Sodium Extended-Release Tablets) compared to placebo in the treatment of bipolar
      disorder, manic or mixed type in children and adolescents ages 10-17 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to the final evaluation in Y-MRS score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex Sodium Extended-Release Tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Current primary diagnosis of bipolar I disorder, mania or mixed type

          -  Outpatient between 10 and 17 years of age

          -  Young Mania Rating Scale score greater than or equal to 20 during screening/washout
             and at Day 1

        EXCLUSION CRITERIA

          -  Axis I other than Attention Deficit Hyperactivity Disorder (ADHD), Obsessive
             Compulsive Disorder (OCD), Oppositional Defiant Disorder (ODD), Conduct Disorder (CD),
             Panic Disorder; or Axis II (e.g., personality disorder) that would interfere with
             compliance or confound interpretation of study results

          -  Current manic episode is drug-induced or secondary to a medical disorder (e.g.,
             anti-depressants, hyperthyroidism)

          -  Expected to require hospitalization for the current manic episode

          -  Participation in psychotherapy that was started within the past 3 months, or if any
             significant changes are anticipated

          -  Has taken atomoxetine or has taken allowed stimulant medication that has not been
             stable for at least 3 months prior to Day 1, or a dosage adjustment is expected during
             the study, or that may worsen mood symptoms

          -  Unable to swallow tablets

          -  Has received depot psychoactive medication within one inter-injection interval of Day
             1

          -  Urine toxicology screen is positive for phencyclidine (PCP), opiates, cocaine,
             barbiturates, benzodiazepines or amphetamines

          -  History of alcohol or substance dependence within past 3 mos. or substance abuse
             within past month

          -  History of failed treatment on adequate Depakote (DR or ER) for a manic episode within
             past 12 months

          -  Has taken Depakote (DR or ER) regularly for the current manic episode

          -  Has serious violent, homicidal, or suicidal ideation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Information</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Clinical Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain West Clinical Trials</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cientifica Inc at Praire View, Inc.</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU - Health Science Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brentwood Research Institute</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Oakland Child/Adoles and Family Center</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2003</study_first_submitted>
  <study_first_submitted_qc>August 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2003</study_first_posted>
  <last_update_submitted>August 2, 2006</last_update_submitted>
  <last_update_submitted_qc>August 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2006</last_update_posted>
  <keyword>Bipolar Disorder Type 1 (manic or mixed type)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

